Uncategorized
Shire acquires Foresight Biotherapeutics for $300 million
Shire has acquired privately held Foresight Biotherapeutics for a cash payment of $300 million, according to a press release.The acquisition includes the global rights to FST-100, topical ophthalmic drops that combine 0.6% povidone-iodine and 0.1% dexamethasone to treat infectious conjunctivitis. Shire said there is synergy between the commercial structures of FST-100 and lifitegrast, which are both in late-stage development, the release said.